Matsutani Tomoo, Nagai Yuichiro, Mine Seiichiro, Murai Hisayuki, Saeki Naokatsu, Iwadate Yasuo
Department of Neurological Surgery, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba City, Chiba, 260-8670, Japan.
Acta Neurochir (Wien). 2009 Mar;151(3):263-8; discussion 268. doi: 10.1007/s00701-009-0199-3. Epub 2009 Feb 25.
Akt/Protein kinase B (PKB) is a common downstream molecule of Ras signaling essential for cell survival. In an attempt to find a novel prognostic marker of diffuse astrocytoma, we performed an immunohistochemical analysis of Akt/PKB with regard to patient survival and regrowth patterns.
Twenty-four adult patients with diffuse astrocytoma were similarly managed without early post-operative radiotherapy and followed up for a median period of 7.5 years. They were analysed by immunohistochemistry for Akt/PKB expression as well as p53 protein accumulation, epidermal growth factor receptor (EGFR) expression, and MIB-1 labeling index. The prognostic significance of each molecular covariate was tested by multivariate analysis using Cox's proportional hazard model including age, performance status, and extent of surgical resection.
Akt/PKB overexpression significantly correlated with both shorter overall survival (OS) and progression-free survival (PFS) (p = 0.0110). All the Akt/PKB-positive patients with post-operative residual tumours experienced tumour recurrences, whereas only a small fraction of the Akt/PKB-negative individuals had recurrences (p = 0.0070). Invasive recurrence into surrounding brain occurred only in the Akt/PKB-overexpressed tumours. In contrast, MIB-1 labeling index correlated only with OS, while p53 protein accumulation correlated only with PFS. The Cox's proportional hazard model identified Akt/PKB overexpression as a significant prognostic factor for shorter PFS (p = 0.0117).
These results show that Akt/PKB overexpression would be suggestive of malignant progression and invasive regrowth of diffuse astrocytoma, and it can serve as a novel prognostic marker for this tumour.
Akt/蛋白激酶B(PKB)是Ras信号通路的常见下游分子,对细胞存活至关重要。为了寻找弥漫性星形细胞瘤的新型预后标志物,我们对Akt/PKB进行了免疫组化分析,以研究患者的生存情况和肿瘤复发模式。
24例成年弥漫性星形细胞瘤患者在术后未早期进行放疗,采用相似的治疗方案,并进行了中位时间为7.5年的随访。通过免疫组化分析他们的Akt/PKB表达、p53蛋白积聚、表皮生长因子受体(EGFR)表达和MIB-1标记指数。使用Cox比例风险模型进行多因素分析,以检验每个分子协变量的预后意义,该模型包括年龄、体能状态和手术切除范围。
Akt/PKB过表达与较短的总生存期(OS)和无进展生存期(PFS)均显著相关(p = 0.0110)。所有术后有残留肿瘤的Akt/PKB阳性患者均出现肿瘤复发,而只有一小部分Akt/PKB阴性患者复发(p = 0.0070)。仅在Akt/PKB过表达的肿瘤中出现向周围脑组织的浸润性复发。相比之下,MIB-1标记指数仅与OS相关,而p53蛋白积聚仅与PFS相关。Cox比例风险模型确定Akt/PKB过表达是较短PFS的显著预后因素(p = 0.0117)。
这些结果表明,Akt/PKB过表达提示弥漫性星形细胞瘤的恶性进展和浸润性复发,可作为该肿瘤的新型预后标志物。